AI Analysis Of CT Scans Finds 42.9% Of Patients Have Coronary Inflammation

TL;DR

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

A U.S. study by Biograph using Caristo Diagnostics’ AI analysis of coronary CT scans found elevated inflammation in 42.9% of asymptomatic, low-risk participants. The company-reported findings also suggest routine blood tests and a standard risk calculator did not identify who had inflammation; whether the finding predicts future heart disease or should change care remains unestablished.

Biograph says a U.S. study using Caristo Diagnostics’ AI-powered analysis of coronary CT scans found elevated inflammation around the arteries in 42.9% of asymptomatic, low-risk participants. The result points to inflammation that standard blood tests and conventional cardiovascular risk measures may not detect, but it does not establish that these participants will develop heart disease or benefit from any particular intervention.

The study examined clinically eligible Biograph Black tier members who were described as asymptomatic and low risk. It combined coronary computed tomography angiography (CCTA) imaging with cardiometabolic profiling and used Caristo’s CaRi-Heart technology to assess inflammation around the coronary arteries. Biograph also said the study used Caristo’s CaRi-Plaque technology to assess plaque and stenosis.

According to the company’s report, 42.9% of participants had elevated inflammation in at least one major heart artery, while 17.9% had very high inflammation. The report also says about 47% of participants with no detectable coronary plaque had elevated coronary perivascular inflammation. These percentages describe the study participants, not the general population; the source material does not provide the sample size or detailed participant demographics.

Biograph said routine measures—including ApoB, non-HDL cholesterol, HbA1c, high-sensitivity C-reactive protein and the AHA PREVENT-ASCVD risk calculator—showed no correlation with the inflammation finding and did not identify which participants had it. The company says the clinical study manuscript is available as a preprint. The supplied report does not include enough methodological detail to independently evaluate the analysis or its results.

What CT Inflammation Signals Could Add

The findings highlight a possible gap between assessing conventional risk factors and identifying inflammation around coronary arteries. If further research confirms that this imaging signal predicts later cardiovascular events, it could add information to risk assessment for some people whose symptoms, blood tests and scans for plaque do not indicate elevated risk. For now, that is a possibility raised by the study, not a demonstrated improvement in predicting or preventing heart disease.

The distinction matters because a finding on an AI analysis is not itself evidence that screening everyone with the technology improves health. The study report does not show whether participants with elevated inflammation went on to have heart attacks or other cardiovascular events, nor whether treatment based on the result changes those outcomes. The result should not be read as a diagnosis or as a reason to alter treatment without clinical advice.

Biograph describes CaRi-Heart as having U.S. Food and Drug Administration De Novo marketing authorization for quantifying coronary inflammation from CCTA. That regulatory status concerns the technology; it does not, by itself, establish the long-term prognostic value or clinical benefit of acting on the study’s findings.

How the CT-Based Study Worked

The study used coronary CT angiography, an imaging method that produces pictures of the heart’s arteries, alongside cardiometabolic assessments. Caristo’s CaRi-Heart software analyzes the tissue around coronary arteries to quantify perivascular inflammation. CaRi-Plaque, which the company says has FDA clearance, is used to assess plaque and stenosis. The technologies are designed to provide different measurements from the same broad imaging approach.

Biograph presents the project as its first U.S. study using CaRi-Heart in asymptomatic, low-risk individuals. Its announcement frames the results as evidence that inflammation can appear even when plaque is not detected and conventional risk assessments appear reassuring. The report is from Biograph, which conducted the study in collaboration with Caristo; the information provided does not include an independent review of the results.

The company’s quoted interpretation is that inflammation could precede visible plaque or narrowing. That explanation is a hypothesis about disease development, rather than a conclusion established by the reported prevalence figures alone. The study’s preprint may provide fuller methods and results, but the supplied announcement does not specify its publication date, peer-review status or whether the findings have been replicated.

““42.9% of participants exhibited elevated inflammation with 17.9% of participants exhibiting very high inflammation in at least one major heart artery.””

— Biograph study statement

What the Results Cannot Yet Show

The announcement does not state the number of participants, their age and other demographic details, or the criteria used to define elevated and very high inflammation. It also does not provide event follow-up, so it is unclear whether the participants with elevated readings experienced more heart disease later than those without them.

The study report says routine measures did not correlate with the AI-derived inflammation measurement. The provided material does not include the underlying statistical analyses, confidence intervals or enough information to assess the strength and limits of that finding. It also does not establish whether the result applies beyond the selected group of eligible Biograph members.

Most importantly, the reported prevalence does not show that AI screening reduces heart attacks, that inflammation detected this way should prompt a specific treatment, or that all asymptomatic adults should receive coronary CT scans. Radiation exposure, cost, potential follow-up testing and the balance of benefits and harms are not addressed in the supplied announcement. The company says more research is needed to establish prognostic value and clinical benefit.

Further Validation and Outcome Data

Biograph says the study manuscript is available as a preprint, which readers can consult for further detail. The next evidence needed would include transparent reporting of the methods and participant group, independent validation in other populations, and follow-up showing whether the inflammation measurement predicts cardiovascular outcomes beyond existing assessments.

Research would also need to test whether decisions guided by the measurement improve patient outcomes, rather than simply detecting more abnormalities. Until those questions are answered, the study is best understood as an early report on the prevalence of an AI-derived imaging signal in a specific group—not proof of a new screening standard. People with questions about cardiovascular risk or imaging results should discuss them with a qualified health professional.

Key Questions

What did the study report?

Biograph reported that 42.9% of its asymptomatic, low-risk participants had elevated coronary inflammation on AI analysis of coronary CT angiography scans. The source does not provide the participant count in its announcement.

Does coronary inflammation mean someone has heart disease?

Not on the evidence described in the announcement. The study reported an imaging measurement, including in some participants without detectable plaque; it did not establish that those people had diagnosed heart disease or would later develop it.

Did blood tests identify the participants with inflammation?

Biograph said the routine measures it assessed—including cholesterol markers, HbA1c, high-sensitivity CRP and the AHA PREVENT-ASCVD calculator—did not identify which participants had elevated inflammation. The supplied report does not include detailed statistical results.

Does this mean everyone should get a coronary CT scan?

No such recommendation is established by the reported findings. The announcement does not show that general-population screening or treatment based on the measurement improves health outcomes. Imaging decisions should be discussed with a qualified health professional.

What evidence is still needed?

Researchers need to validate the result in other groups, determine whether the measurement predicts future cardiovascular events, and test whether care guided by it improves outcomes. Biograph itself says further research is needed to establish prognostic value and benefit.

Source: hn